https://doi.org/10.5812/jjcdc.95732

Cancers of Urinary System; Prevalence, Demographic

authors:

avatar Zahra Tolou Ghamari ORCID 1 , *

Isfahan Kidney Transplantation Research Center, Alzahra Research Centers, Isfahan University of Medical Sciences, Isfahan, Iran
Jundishapur Journal of Chronic Disease Care: Vol.8, issue 4; e95732
published online: October 16, 2019
article type: Research Article
received: June 26, 2019
revised: September 5, 2019
accepted: October 4, 2019

how to cite: Tolou Ghamari Z. Cancers of Urinary System; Prevalence, Demographic. Jundishapur J Chronic Dis Care. 2019;8(4):e95732. https://doi.org/10.5812/jjcdc.95732.

Abstract

Objectives:

This investigation aimed to clarify the period prevalence (PP) and incidence rate (Irs) related to cancers of the urinary system in Isfahan province, Iran.

Methods:

Recorded data were obtained from the Isfahan Cancer Registry. The location of cancers was distinguished from the related established topography code (C64 - C68). Period prevalence (PP) and Irs was identified per 100000 persons.

Results:

There were 2117 patients with urinary system cancers. The mean age ± SD was 63.6 ± 14.9 years old, which in 62% ranged between 20 and 70 years. A value of 42.5 was calculated for PP that was associated with values of 66.4 for males and 17.9 for females (P < 0.001). The total PP corresponded to values of 33.2 for bladder, 8.1 for a kidney, 0.42 for renal pelvis, 0.36 for ureter and 0.38 for other unspecified related organs. Of these populations, the estimated living cases corresponded to 368 females and 1513 males.

Conclusions:

The PP for urinary system cancers in male population was 3.7 times higher than females. There was a 23.2% increase in the Irs over the study period. These findings highlighted the advantage of a focus on the risk of urinary system diseases, its evidence based pharmacotherapy and surgical management of such patients. In this process, providing clinical drug-management has potential importance in Iran.

1. Background

According to a publication by Yaxley in 2016 (1), the cancers of urinary system are common and include a series of injuries encompassing small benign tumors to destructive neoplasms with high morbidity. The urinary tract is lined by epithelium extending from the renal tubule proximallly to the external urethral orifice distally. These epithelial cells are recognized as the urothelium or transitional cells. They are highly specialized cells with elasticity and variable shape. Any segment of the urothelium can be affected by malignant transformation. In the year 2008, 12.7 million cases with cancer, and 7.6 million cancer-related deaths were reported by Globocan (2). Siegel et al., in 2013 reported (3) that advanced urothelial carcinoma accounts for about 15,000 deaths in the United States annually. The most common malignancy reported is urinary bladder cancer. The report indicates a higher ratio (2:1) of upper tract urothelial carcinoma in men than in women. The main risk factors are occupational exposure, various chemical carcinogens and cigarette smoking (4). Histological tumor classification is an established predictive factor of renal cell carcinoma (5). Cytologically and histologically, overexpression of p16INK4a has been recognized in urothelial malignancies. Therefore, there are potential implications for the clinical management of patients after the conservative treatment of non-muscle-invasive urothelial carcinoma. Furthermore, a long-term assessment of p16/Ki-67 double labeling has been revealed to distinguish high-grade urothelial cancer cells and particular individual development within a 12-month period (6). In a population with clear-cell renal cell carcinoma collecting system invasion is related to lack of prediction (7). Total existence and progression-free survival in patients with urinary system cancer could be associated with high serum levels of lactate dehydrogenase (8). Study of kidney cancer in rural Illinois showed that the kidney and renal pelvis cancer incidence was higher in urban counties whereas mortality was higher in rural counties (9). In Hong Kong in year 2012, a report indicated that 9.6% of new cancer cases were related to urological malignancy (10). Study of 198 patients with bladder cancer (BC) and 396 healthy individuals in Shiraz, Iran mentioned that a potential risk factor could be the use of opium (11).

As the essential knowledge of public health strategy, the use of epidemiologic information associated with urinary systems, is the need to provide a knowledge causes of disease and its pharmacotherapy management.

2. Objectives

As there is considerable variation in the distribution of diseases worldwide, therefore the aim of this study was to show up-to-date estimates of crude rate, incidence rates and differences in rates between men and women of urinary system cancer in Isfahan, Iran.

3. Methods

This retrospective study was conducted to the Isfahan Kidney Transplantation Research Center (IKTRC) and approved by the Isfahan Deputy of Research Committee via the Ethics Committee code number (295115). Cancer data was obtained from the Isfahan Cancer Registry located in deputy of health. The data considered in this study belonged to the years between March 2011 to March 2015. The cancer sites studied were characterized according to the international classification of diseases (ICD-O; third edition). All cancers were defined by topography code. For example, kidney was defined by topography code C64, renal pelvis by the topography code C65, ureter by topography code C66 and bladder by topography code C67. There was not any exclusion criterion. After removing patient name and surname, demographic data such as age and gender, final code for cancer diagnosis and date of reported cancer were recorded. Variables such as gender, being alive/dead, year of the report were expressed by frequency, percentage, period prevalence and incidence rate. The total population of Isfahan city was obtained from the Isfahan/Program and Budget Management Organization. Period prevalence was calculated as the proportion of total cases over the period of the years 2011 - 2015/to populations at risk during the same time period × 100000. Cancer incidence rate (CIR) was calculated as dividing new cases of cancer during a given time period/to populate at risk during the same time period × 100000. Analysis of data was carried out using the statistical package for social science (SPSS® version 20 IBM Corp., Armonk NY, USA). An age that was a continuous variable was expressed by mean ± standard deviation (SD) (12-20).

4. Results

Table 1 shows demographic and epidemiological characteristic in 2117 patients with urinary system cancers. The study population comprised of 440 females and 1677 males. The total period prevalence was calculated as 42.5 per 100000 persons (Figure 1) that corresponded to: 33.2 for bladder, 8.1 for a kidney, 0.42 for renal pelvis, 0.4 for ureter and 0.8 for other and unspecified urinary organs. With the mean age ± standard deviation of 63.6 ± 14.9 years, age related to urinary system cancers in 1%, 62% and 37% were related to age under 20, between 20 to 70 and 70 to 100 years of life respectively (Figure 2). Death reported-data was associated with 11% of total cases. The rate of males to females was 83% for bladder, 77% for kidney, 62% for renal pelvis, 94% for ureter and 74% for other and unspecified urinary organs. Incidences of urinary system cancer were calculated as: 9.9 (2011 to 2012), 10.5 (2012 to 2013), 9.9 (2013 to 2014) and 12.2 (2014 to 2015) per 100000 persons (Figure 3).

Table 1.

Demographic and Epidemiological Characteristics in Patients with Urinary System Cancers

Sites of CancersTotal CasesPeriod PrevalenceEstimated Living CasesEstimated Deaths
Both SexesFemalesMalesBoth SexesFemalesMales
Urinary system211742.51881368151323672164
Bladder165533.21499239126015641115
Kidney4048.134872276562135
Renal pelvis210.429271266
Ureter180.3618117000
Other and unspecified urinary organs190.387161248
Cancer period prevalence according to each location within urinary system
Cancer period prevalence according to each location within urinary system
Figure 1.

Cancer period prevalence according to each location within urinary system

Distribution of age in patients with urinary system cancer
Distribution of age in patients with urinary system cancer
Figure 2.

Distribution of age in patients with urinary system cancer

Incidence of urinary system cancers
Incidence of urinary system cancers
Figure 3.

Incidence of urinary system cancers

5. Discussion

Urinary system cancers are common and impose an important cost, weight on the health system. Previous publications reported that BC and kidney cancers are the most common tumors of the urinary system, that make up to 5% of all cancers globally (21). As there has been diminutive evidence-based data associated with occurrence of urinary system cancers in the Iranian/Isfahan population, therefore this study conducted an analysis obtained from the population-based cancer registry.

In agreement with previous studies of western countries which specified an increasing trend toward incidence of urinary bladder and kidney cancers (22), in this study incidence of urinary system cancers 23.2% was increased between 2011 and 2015. Previous publications confirmed that, there is a change to older-in-age scattering in Iran as a developing country (23). In agreement with previous publications that mentioned the mean age of diagnosis of 65 years (24), in this study also the mean age of patients was also 63.6 years old.

The result of this study is in agreement with the Australian Institute of Health and Welfare report that confirmed bladder cancer as the most common cancers with a rise in incidence (25). De et al. in 2014 studied (26) incidence of kidney cancer between 1986 and 2007. The age-standardized incidence rate per 100,000 rose from 13.4 to 17.9 in males and 7.7 to 10.3 in females. In this study the period prevalence was ranked for BC with a value of 33.2 and 8.1 for kidney per 100000 persons respectively. The PP, among males and females was significantly different (66.4 vs. 17.9, P < 0.001).

The estimated deaths correlated to 236 out of 2117 (11.1%) patients with urinary system cancers. Reported mortality in cancer of renal pelvis was 57.2% and this is in agreement with a published report from Bailey et al. in 2017, declaring that among patients with clear-cell renal cell carcinoma, collecting system invasion is associated with poor prognosis (6).

The results of this study showed that urinary bladder, kidney cancer followed an increasing trend in incidence, mortality and prevalence in Isfahan, Iran (14-20, 26-32). The implications of this investigation could be mentioned as the following suggestions: (1) the health care system should provide a model-based strategy to improve access to specialized medical, pharmacological and surgical facilities; (2) consideration is needed toward the reality for scheduling health system improvements, particularly referral systems; (3) preventing significant difficulties by equality of management for patient satisfaction; (4) attention toward financial management by study of epidemiology and pharmacotherapy.

5.1. Conclusions

From the year 2011 to 2015, there were 2117 patients with urinary system cancers in Isfahan Province. The mean age ± SD was 63.6 ± 14.9 years. In 62% of total population age ranged between 20 and 70 years. The PP was 42.5 per 100000 persons. Total PP corresponded to 66.4 for males versus 17.9 for females (P < 0.001). The PP was 33.2 for bladder, 8.1 for a kidney, 0.42 for renal pelvis, 0.36 for ureter and 0.38 for other unspecified related organs. There were living cases comprised of 368 females and 1513 males. There was a 23.2% increase in the Irs over the study period.

An appropriate judgment and discussion about the trends and changes are needed to investigate the incidence of urologic cancers over time. For future plans additional research toward drug-management associated with urinary system cancers in Iran recommended.

Acknowledgements

References

  • 1.

    Yaxley JP. Urinary tract cancers: An overview for general practice. J Family Med Prim Care. 2016;5(3):533-8. [PubMed ID: 28217578]. [PubMed Central ID: PMC5290755]. https://doi.org/10.4103/2249-4863.197258.

  • 2.

    Aydin S, Boz MY. Rapid changes in the incidence of urinary system cancers in Turkey. Turk J Urol. 2015;41(4):215-20. [PubMed ID: 26623151]. [PubMed Central ID: PMC4621150]. https://doi.org/10.5152/tud.2015.45548.

  • 3.

    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30. [PubMed ID: 23335087]. https://doi.org/10.3322/caac.21166.

  • 4.

    Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24(10):730-4. [PubMed ID: 28543959]. https://doi.org/10.1111/iju.13376.

  • 5.

    Piaton E, Advenier AS, Carre C, Decaussin-Petrucci M, Mege-Lechevallier F, Hutin K, et al. p16/Ki-67 dual labeling and urinary cytology results according to the new Paris System for reporting urinary cytology: Impact of extended follow-up. Cancer Cytopathol. 2017;125(7):552-62. [PubMed ID: 28371465]. https://doi.org/10.1002/cncy.21853.

  • 6.

    Bailey GC, Boorjian SA, Ziegelmann MJ, Westerman ME, Lohse CM, Leibovich BC, et al. Urinary collecting system invasion is associated with poor survival in patients with clear-cell renal cell carcinoma. BJU Int. 2017;119(4):585-90. [PubMed ID: 27696652]. https://doi.org/10.1111/bju.13669.

  • 7.

    Zhang Y, Xu T, Wang Y, Zhang H, Zhao Y, Yang X, et al. Prognostic role of lactate dehydrogenase expression in urologic cancers: A systematic review and meta-analysis. Oncol Res Treat. 2016;39(10):592-604. [PubMed ID: 27710971]. https://doi.org/10.1159/000449138.

  • 8.

    Moch H. [The WHO/ISUP grading system for renal carcinoma]. Pathologe. 2016;37(4):355-60. German. [PubMed ID: 27271258]. https://doi.org/10.1007/s00292-016-0171-y.

  • 9.

    Sadowski DJ, Geiger SW, Mueller GS, Zahnd WE, Alanee SR, McVary KT. Kidney cancer in rural illinois: Lower incidence yet higher mortality rates. Urology. 2016;94:90-5. [PubMed ID: 27215485]. https://doi.org/10.1016/j.urology.2016.05.022.

  • 10.

    Yee CH, Ng CF. Urological malignancy in Hong Kong: The trend and the practice. Jpn J Clin Oncol. 2015;45(12):1103-6. [PubMed ID: 26450701]. https://doi.org/10.1093/jjco/hyv145.

  • 11.

    Akbari M, Naghibzadeh-Tahami A, Khanjani N, Baneshi MR, Kamali E, Hesampour M, et al. Opium as a risk factor for bladder cancer: A population-based case-control study in Iran. Arch Iran Med. 2015;18(9):567-71. [PubMed ID: 26317596].

  • 12.

    Mazdak H, Tolou-Ghamari Z. Preliminary study of prevalence for bladder cancer in Isfahan province, Iran. Arab J Urol. 2018;16(2):206-10. [PubMed ID: 29892483]. [PubMed Central ID: PMC5992262]. https://doi.org/10.1016/j.aju.2017.11.017.

  • 13.

    Tolou Ghamari Z. Prevalence of lung cancer in Isfahan province, Iran. J Egypt Natl Canc Inst. 2018;30(2):57-9. [PubMed ID: 29691096]. https://doi.org/10.1016/j.jnci.2018.03.001.

  • 14.

    Tolou Ghamari Z. Thyroid cancer in Isfahan province, Iran; Prevalence and demographic characteristics. Jundishapur J Chronic Dis Care. 2019;8(1). e86864. https://doi.org/10.5812/jjcdc.86864.

  • 15.

    Tolou_Ghamari Z. Prevalence of stomach cancer in Isfahan Province, Iran. Gulf J Oncol. 2018;8(1).

  • 16.

    Tolou-Ghamari Z. Prevalence of Skin cancer in Isfahan province, Iran. Jentashapir J Health Res. 2018;9(2):82743. https://doi.org/10.5812/jjhr.82743.

  • 17.

    Mazdak H, Tolou-Ghamari Z, Gholampour M. Investigation of bladder cancer incidence in Isfahan, Iran. Tehran Univ Med J. 2019;77(4):252-6.

  • 18.

    Tolou-Ghamari Z. Investigation of genital system cancers prevalencein Isfahan, Iran. Indones J Cancer. 2019;13(2):25. https://doi.org/10.33371/ijoc.v13i2.631.

  • 19.

    Mazdak H, Khorrami AK, Tolou-Ghamari Z. Urethral stricture: Investigation of demographic characteristics in two tertiary hospitals in Isfahan/Iran. Am J Exp Clin Res. 2019;6(3):355-8.

  • 20.

    Tolou-Ghamari Z. Prevalence of kidney, renal pelvis, and ureter cancers in Isfahan province, Iran. J Arch Mil Med. 2019;7(1-2):e95457.

  • 21.

    Ferlay J, Shin HR, Bray F, Forman D, Mathers C. Globocan 2008 V1. 2, cancer incidence and mortality world-wide: IARC cancer base No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.

  • 22.

    Yang Y, Xie L, Zheng JL, Tan YT, Zhang W, Xiang YB. Incidence trends of urinary bladder and kidney cancers in urban Shanghai, 1973-2005. PLoS One. 2013;8(12). e82430. [PubMed ID: 24324788]. [PubMed Central ID: PMC3853415]. https://doi.org/10.1371/journal.pone.0082430.

  • 23.

    Malekmakan L, Khajehdehi P, Pakfetrat M, Malekmakan A, Mahdaviazad H, Roozbeh J. Prevalence of chronic kidney disease and its related risk factors in elderly of southern iran: A population-based study. ISRN Nephrol. 2013;2013:427230. [PubMed ID: 24967234]. [PubMed Central ID: PMC4045432]. https://doi.org/10.5402/2013/427230.

  • 24.

    Woodford C, Yao C. Essential med notes 2013. Toronto: Toronto Notes for Medical Students Inc; 2013.

  • 25.

    Australian Institute of Health. Cancer survival and prevalence in Australia: Period estimates from 1982 to 2010. Canberra, Australia: AIHW; 2012.

  • 26.

    De P, Otterstatter MC, Semenciw R, Ellison LF, Marrett LD, Dryer D. Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986-2007. Cancer Causes Control. 2014;25(10):1271-81. [PubMed ID: 25034462]. [PubMed Central ID: PMC4194017]. https://doi.org/10.1007/s10552-014-0427-x.

  • 27.

    Tolou-Ghamari Z, Shaygannejad V, Ashtari F. Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the Isfahan Kashani hospital. Int J Prev Med. 2013;4(Suppl 2):S274-8. [PubMed ID: 23776737]. [PubMed Central ID: PMC3678231].

  • 28.

    Shaygannejad V, Tolou-Ghamari Z. What is the real fate of vitamin D in multiple sclerosis? Int J Prev Med. 2013;4(Suppl 2):S159-64. [PubMed ID: 23776718]. [PubMed Central ID: PMC3678212].

  • 29.

    Tolou Ghamari Z, Mehavari Habibabadi J, Palizban AA. Evidence-based pharmacotherapy of epilepsy. Arch Neurosci. 2014;2(2). https://doi.org/10.5812/archneurosci.18468.

  • 30.

    Tolou-Ghamari Z, Tadayon F, Mazdak H. Prevalence of liver cancer in Isfahan province, Iran. Indones J Cancer. 2018;12(2):56. https://doi.org/10.33371/ijoc.v12i2.578.

  • 31.

    Tolou-Ghamari Z. Prevalence of breast cancer in Isfahan province, Iran. Womens Health Bull. 2018;5(4). e82678. https://doi.org/10.5812/whb.82678.

  • 32.

    Tolou Ghamari Z. Prevalence of stomach cancer in Isfahan province, Iran. Jundishapur J Chronic Dis Care. 2019;8(1):42-5.